Use of combined drugs in treatment of respiratory viral infections
Diseases caused by viral infections of the respiratory tract occupy the first place in prevalence among all viral pathologies. Pathogens such as influenza virus, respiratory syncytial virus, rhinovirus and others that are dangerous not only due to their direct negative effect on the human body, but...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Remedium Group LLC
2016-12-01
|
| Series: | Медицинский совет |
| Subjects: | |
| Online Access: | https://www.med-sovet.pro/jour/article/view/1581 |
| Summary: | Diseases caused by viral infections of the respiratory tract occupy the first place in prevalence among all viral pathologies. Pathogens such as influenza virus, respiratory syncytial virus, rhinovirus and others that are dangerous not only due to their direct negative effect on the human body, but by the fact that they strengthen the course of other inflammatory diseases of the respiratory tract, for example bronchial asthma. Development of new molecular research methods in immunology allowed revealing in detail the peculiarities of the life cycle of certain respiratory viruses, and understanding of the mechanisms of antiviral defense. According to modern concepts the immune system is a delicate and complicated mechanism of the antiviral response, in which one of the main roles is played by cells containing on their surface CD4-receptors. Also many studies proved the key role of interferon I, II and III type as the first line of antiviral defense. The knowledge accumulated as of today in the field of virology and immunology allows us to implement a comprehensive approach in the development of new antiviral drugs with the aim to achieve greater efficiency. This approach was successfully implemented with the creation of the drug Ergoferon containing a combination of affinity purified antibodies to CD4, interferon-γ and histamine in a releaseactive form with antiviral, anti-inflammatory and antihistamine activity. Influence on the CD4-receptors enables the drug to activate the cascade of immunologic responses aimed at improving the protective properties of the body – to fight infectious agents, primarily viral in origin. Effects on the IFN system make an equivalent contribution to the effect on CD4-receptor to the antiviral properties of the drug. A unique combination of properties, high level of evidence of clinical efficacy, good tolerability and no adverse drug effects can refer Ergoferon to effective and safe drugs for treatment of the main respiratory viral infections. |
|---|---|
| ISSN: | 2079-701X 2658-5790 |